Obesity Management for Cardiovascular Disease Prevention (Recorded Webinar)
Obesity is a chronic, serious life threatening disease, but treatments exist. Obesity is associated with an increased risk of CVD and CV-associated mortality. Thus, weight management is an important component of comprehensive CV preventive efforts. GLP-1 receptor agonists are effective FDA-approved agents for weight management. Moreover, GLP-1 receptor agonists have been shown to reduce CVD risk in patients with T2D, and additionally semaglutide has been shown to reduce CVD events in persons with overweight/obesity at high CV risk but without diabetes. Thus, on a background of healthy lifestyle efforts, GLP-1 RAs should be considered by cardiologists and other HCPs as a treatment option for obesity to reduce CVD risk.
CME/CE Expiration Date: 2/8/27
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific LIVE presentation.
1) To understand the cardiovascular risks associated with excess adiposity
2) To review lifestyle, surgical, and pharmacological strategies for weight management and their impact on reducing cardiovascular disease risk
3) To highlight the role that cardiovascular specialists and other clinicians play in addressing weight management for the purposes of cardiovascular disease prevention
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.